$89,000 Orphan Drug Gets A New Owner 鈥 And Likely A New Price
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
Drug Costs
621-640 of 705 results
-
-
Treating Cancer: Hope Vs. Hype
Sticker Shock Forces Thousands Of Cancer Patients To Skip Drugs, Skimp On Treatment
A growing number of patients fail to fill prescriptions because the cost of cancer drugs is too high.
By Liz Szabo -
Repeal & Replace Watch
Trump, Dems Look For Common Ground On Drug Prices
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government鈥檚 ability to negotiate drug prices, but it鈥檚 not clear it would have much impact or will gain support.
-
Three Key Senators Ask GAO To Investigate Possible Abuses Of The Orphan Drug Act
Amid an uproar over high drug prices, three GOP senators are asking the Government Accountability Office to investigate whether the Orphan Drug Act is being abused.
By Sarah Jane Tribble and Sydney Lupkin -
Patient Advocacy Groups Rake In Donations From Pharma
A new study shows that 83 percent of the largest patient advocacy groups take contributions from drug, medical device or biotech firms.
By Emily Kopp -
The Orphan Drug Machine
5 Reasons Why An $89,000 Drug Has Congress Fuming
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
By Sarah Jane Tribble and Sydney Lupkin -
Repeal & Replace Watch
Former FDA Chief Cites 5 Things To Watch On Drug Approvals And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
By Sydney Lupkin and Sarah Jane Tribble -
The Orphan Drug Machine
Drugmaker Marathon 鈥楶ausing鈥 Delivery Of $89,000-A-Year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
By Sarah Jane Tribble and Sydney Lupkin -
Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
-
Drugmaker Kaleo Raises Price Of Lifesaving Drug By Thousands
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
-
Drug Prices, Opioids, And Obamacare: A Conversation With Assemblyman Jim Wood
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
-
The Orphan Drug Machine
Sky-High Prices For Orphan Drugs Slam American Families And Insurers
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
By Sarah Jane Tribble and Sydney Lupkin -
The Orphan Drug Machine
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren鈥檛 new or were repurposed multiple times, an investigation shows.
By Sarah Jane Tribble and Sydney Lupkin -
The Orphan Drug Machine
Timeline: The Orphan Drug Act
Follow the twists and turns of the orphan drug industry over the past three decades.
-
The Orphan Drug Machine
Interactive: How Orphan Drugs Win The ‘Monopoly’ Game
Check out all the drugs the FDA has approved to treat rare diseases. You can search by brand name, or by disease, and see familiar names that were first sold on the mass market or all the drugs that won FDA approval to treat more than one rare disease.
-
The Orphan Drug Machine
Video: Former U.S. Rep. Henry Waxman Shares Deep Concerns About Orphan Drugs
The former Congressman championed the Orphan Drug Act decades ago but now he fears it鈥檚 being manipulated to make money.
-
Medicare Pays For A Kidney Transplant, But Not The Drugs To Keep It Viable
The federal government pays for kidney transplants. But the program only pays for essential anti-rejection drugs for three years. Many people can't afford them and can end up losing the kidney.
-
Alleged Scheme To Fix Generic Drug Prices Started At Dinners And ‘Girls Nights Out’
Investigators claim drugmaker employees met in secret at restaurants, golf outings and at 鈥淕irls Night Out鈥 to raise generic drug prices.
-
Faced With Unaffordable Drug Prices, Tens Of Millions Buy Medicine Outside U.S.
Eight percent of those polled by the Kaiser Family Foundation say they have purchased medications outside of the U.S. to save money.
By Rachel Bluth -
In Colorado, A Low-Price Drug Cocktail Will Tamp Down Cost Of Death With Dignity
Advocates want alternatives to drugmaker's pricey pills for those who choose to die in Colorado and elsewhere.